ARCA biopharma, Inc. Aktie News

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 ...

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P.

ORKA's main bet is by targeting psoriasis with ultra-durable biologics like ORKA-001 (IL-23) in Phase 2a and ORKA-002 (IL-17A/F) in Phase 1. ORKA-001 could offer significant clinical benefits with only 1 to 2 doses per year. Its Phase 1 suggests a ~100-day half-life. But interestingly, it's possible that higher exposure may drive higher clearance and potential off-treatment remission.

Appoints accomplished commercial leader Chris Martin to its Board of Directors Appoints accomplished commercial leader Chris Martin to its Board of Directors

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis.

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIP...